Back to News
Market Impact: 0.2
VolitionRx Signs LOI with Missionpharma to explore the Development and Launch of Volition's Lateral Flow Technology for NETosis Worldwide
Source: PR Newswire
Healthcare & BiotechCompany Fundamentals
VolitionRx announced that it executed a non-binding letter of intent with Missionpharma A/S, a Danish global seller and distributor. The provided article text contains no further details on the proposed arrangement, its financial terms, or a binding commitment.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
VNRX0.50
More News
- SK Hynix Posts Record Profit Amid AI Rush
- SK Hynix third-quarter profit sharply beats estimates on AI memory boost
- Anthropic's IPO could be 'speculative fiction' or a 'generational moment' — investors are split
- Anthropic Gives Traders a Pure-Play Bet on Frontier AI
- Analysis-Hold or sell? High Treasury yields spur US banks to rethink bond portfolios
- VCs will make billions on Anthropic’s IPO, but Amazon is set to make much (much) more